Denali's AVLAYAH Launch Exceeds Expectations, But Deep Risks Remain

What happened

Denali Therapeutics announced at a Bank of America conference that the early commercial launch of AVLAYAH (tividenofusp alfa) for Hunter syndrome is ahead of expectations following its accelerated approval on March 24, 2026. This provides initial validation of the company's first commercial product and its Transport Vehicle platform, but comes with caveats: the approval was based on surrogate biomarkers, and the long-term commercial trajectory remains unproven. The DeepValue report had assigned a WAIT rating due to binary regulatory risk and a crowded bull consensus, with a base case of $24/share and downside to near-cash levels of $9 if the FDA or clinical data disappointed. While early launch momentum is encouraging, the company faces significant ongoing cash burn, a heavy dependence on tividenofusp's success, and upcoming binary readouts from LRRK2 and other pipeline programs later in 2026. The stock has already rallied from its $12-14 lows in 2025, and the current price near $18 reflects some of this optimism, limiting near-term upside until more concrete revenue data emerges.

Implication

The initial launch data modestly reduces downside risk, as it suggests tividenofusp is gaining adoption among physicians and patients more quickly than modeled. However, the DeepValue report's base-case implied value of $24 already assumed a successful launch, so the upside from current levels is limited without sustained revenue beats or positive phase 2/3 data from other pipeline assets. Key catalysts to monitor: (1) Q2 2026 earnings with first quarterly sales figures; (2) LUMA Phase 2b readout for BIIB122 in Parkinson's in 2H 2026; (3) FDA's final label and post-marketing requirements. Until these events clarify, the risk/reward remains unfavorable at current levels, with a potential 40-50% downside if any catalyst disappoints. Investors should consider trimming positions if the stock approaches $22-24 and wait for a better entry near $14-16.

Thesis delta

The DeepValue thesis previously centered on a binary outcome around tividenofusp approval and early launch. The news that launch is ahead of expectations shifts the narrative from 'will it launch?' to 'how fast will it scale?' This reduces the probability of the bear case (35% probability of $9/share) and increases confidence in the base case (45% probability of $24/share), but does not justify raising the rating to a buy. The crowded consensus and remaining pipeline risks mean the stock still trades above our attractive entry of $12. The thesis now awaits tangible revenue data and pipeline milestones for confirmation.